早期使用CAR- T治疗可显示多发性骨髓瘤患者的持续缓解,在30个月后80. 5%的患者没有进展. A CAR-T therapy showed lasting remissions in multiple myeloma patients when used early, with 80.5% progression-free at 30 months.

更新的CARTITUDE-4第3期试验结果显示,在标准风险的复发或耐药多发性骨髓瘤患者中,单次输注CARVYKTI® (ciltacabtagene autoleucel) 导致了长期无治疗缓解,在第二线治疗中治疗30. 5个月后,仍无进展. Updated Phase 3 CARTITUDE-4 trial results show that a single infusion of CARVYKTI® (ciltacabtagene autoleucel) led to lasting treatment-free remissions in standard-risk patients with relapsed or refractory multiple myeloma, with 80.5% remaining progression-free at 30 months when treated as early as second-line therapy. 所有病人在12个月后达到最低的残余疾病负性完全反应,在30个月后保持无累进状态。 All patients achieving minimal residual disease-negative complete response at 12 months stayed progression-free at 30 months. 调查结果表明,早先的使用可能会改善结果,可能因为免疫机能改善,并支持改变治疗模式。 Findings suggest earlier use may improve outcomes, potentially due to better immune fitness, and support shifting treatment paradigms. CARVYKTI是第一种CAR-T疗法,显示与标准治疗相比,总体生存效益显著,全球有9 000多名病人接受治疗。 CARVYKTI® is the first CAR-T therapy to show a significant overall survival benefit over standard treatments, with over 9,000 patients treated globally.